Article
CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.
Environmental toxicology and pharmacology - 1 Dec 2017
Varnai Reka, Sipeky Csilla, Nagy Lajos, Balogh Sandor, Melegh Bela
Abstract excerpt
The purpose of this work was to investigate the contribution of CYP2C9 and VKORC1 to acenocoumarol (AC) dose variability, bleeding events in Hungary. The study recruited 117 patients on long-term AC therapy (INR 2-3), and 510 healthy individuals to model the findings. Patients were genotyped for alleles proved to affect lower AC overdose CYP2C9*2, CYP2C9*3, VKORC1*2. Additionally, we tested VKORC1*3, VKORC1*4 to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.